[Federal Register Volume 59, Number 11 (Tuesday, January 18, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-1047]


[[Page Unknown]]

[Federal Register: January 18, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 94N-0004]

 

Animal Drug Export; Abamectin

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that 
Merck Research Laboratories, Division of Merck & Co., Inc., has filed 
an application requesting approval for export of the bulk animal drug 
substance abamectin to the Netherlands where it will be further 
exported to Australia or New Zealand either as the bulk material or as 
the formulated injectable product. The drug is administered to cattle 
for the control of certain internal and external parasites.

ADDRESSES: Relevant information on this application may be directed to 
the Dockets Management Branch (HFA-305), Food and Drug Administration, 
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
person identified below. Any future inquiries concerning the export of 
food animal drugs under the Drug Export Amendments of 1986 should also 
be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Benjamin A. Puyot, Center for 
Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-594-1646.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
provide that FDA may approve applications for the export of drugs that 
are not currently approved in the United States. Section 802(b)(3)(B) 
of the act sets forth the requirements that must be met in an 
application for approval. Section 802(b)(3)(C) of the act requires that 
the agency review the application within 30 days of its filing to 
determine whether the requirements of section 802(b)(3)(B) have been 
satisfied. Section 802(b)(3)(A) of the act requires that the agency 
publish a notice in the Federal Register within 10 days of the filing 
of an application for export to facilitate public participation in its 
review of the application. To meet this requirement, the agency is 
providing notice that Merck Research Laboratories, Division of Merck & 
Co., Inc., Rahway, NJ 07065, has filed an application requesting 
approval for the export of the bulk animal drug substance abamectin to 
the Netherlands where it will be further exported to Australia or New 
Zealand either as the bulk material or as the formulated injectable 
product. The drug is administered to cattle for control of certain 
internal and external parasites. The application was received and filed 
in the Center for Veterinary Medicine on December 30, 1993, which shall 
be considered the filing date for purposes of the act.
    Interested persons may submit relevant information on the 
application to the Dockets Management Branch (address above) in two 
copies (except that individuals may submit single copies) and 
identified with the docket number found in brackets in the heading of 
this document. These submissions may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.
    The agency encourages any person who submits relevant information 
on the application to do so by January 28, 1994, and to provide an 
additional copy of the submission directly to the contact person 
identified above, to facilitate consideration of the information during 
the 30-day period.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
Center for Veterinary Medicine (21 CFR 5.44).

    Dated: January 7, 1994.
 Robert C. Livingston,
 Director, Office of New Drug Evaluation, Center for Veterinary 
Medicine.
[FR Doc. 94-1047 Filed 1-14-94; 8:45 am]
BILLING CODE 4160-01-F